 |
24 Diseases |  |
12 Trials |
|
12 Trials |  |
871 News |  |
| «12345678910111213» |
- | Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
Preclinical, Journal: Age-dependent anticonvulsant actions of perampanel and brivaracetam in the methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) model of seizures in developing rats. (Pubmed Central) - Sep 10, 2021
These data indicate that while the efficacy of these drugs may be limited for neonatal seizures, their efficacy increases over early postnatal development.
- Briviact (brivaracetam) / UCB
Focal Seizures Presenting as Dysphagia (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_358;
Black boxes denote left temporal head region electrode channels. Black arrows denote emergence of subtle left rhythmic delta frequency activities.
- ||||| brivaracetam / Generic mfg.
Enrollment closed, Enrollment change: Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Sep 8, 2021
P3, N=257, Active, not recruiting, Sponsor: UCB Pharma SA
Black arrows denote emergence of subtle left rhythmic delta frequency activities. Enrolling by invitation --> Active, not recruiting | N=600 --> 257
- | brivaracetam / Generic mfg.
New P1 trial: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas (clinicaltrials.gov) - Aug 31, 2021
P1, N=30, Not yet recruiting, Sponsor: University of Rochester
- ||| Briviact (brivaracetam) / UCB
Clinical: FDA has expanded the indication for brivaracetam for partial-onset seizures in patients as young as 1 month of age. https://t.co/BW755rIkj3 (Twitter) - Aug 30, 2021
- || Briviact (brivaracetam) / UCB
Review, Journal: A review of the drug-drug interactions of the antiepileptic drug brivaracetam. (Pubmed Central) - Aug 20, 2021
Dose adjustment should be considered when brivaracetam is coadministered with the more potent CYP inducer, rifampin...John's wort. In summary, brivaracetam (50-200 mg/day) has a favorable pharmacokinetic profile and is associated with few clinically relevant drug-drug interactions.
- || Clinical, Review, Journal: Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review. (Pubmed Central) - Aug 20, 2021
The evidence for the use of ASDs in RSE beyond that in current guidelines is low, but several effective and well-tolerated options are available that should be considered in this patient population. More so than in any other population, advance care planning, advance directives, and medical ethical aspects have to be considered carefully before and during therapy.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: An update on brivaracetam for the treatment of pediatric partial epilepsy. (Pubmed Central) - Aug 19, 2021
However, a positive response was also achieved in patients affected by some encephalopathic epilepsies. Comparative efficacy studies between BRV and other ASMs, in addition to well-designed RCTs that include larger pediatric populations are needed to better define the role and potentiality of this ASM.
- | brivaracetam / Generic mfg.
Phase classification, Monotherapy: EXPAND: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - Aug 11, 2021
P3, N=160, Recruiting, Sponsor: UCB Biopharma SRL
Comparative efficacy studies between BRV and other ASMs, in addition to well-designed RCTs that include larger pediatric populations are needed to better define the role and potentiality of this ASM. Phase classification: P2/3 --> P3
- || Briviact (brivaracetam) / UCB
Clinical, Retrospective data, Journal: Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis. (Pubmed Central) - Aug 7, 2021
P3
Phase classification: P2/3 --> P3 Adjunctive BRV showed efficacy and was generally well tolerated in adults with focal seizures independent of the number of previous ASMs.
- [VIRTUAL] COMPARISON OF THE EFFECTS OF NEW ANTI-SEIZURE DRUGS (ASDS) ON CARDIAC AUTONOMIC CONTROL IN PATIENTS WITH TEMPORAL LOBE EPILEPSY (TLE) (Free Communication C) - Aug 6, 2021 - Abstract #WCN2021WCN_75;
The aim of this study is to assess, using the spectral analysis of HRV, new anti-seizure medication (ASMs) - Perampanel (PER), Lacosamide (LCS), Eslicarbazepine (ECB) and Brivaracetam (BRV) - effects on CAF in patients with TLE. Eighty patients with diagnosis of TLE were enrolled. Our study demonstrates that the use of PER, compared to other new ASMs, provide the safest modification of cardio-autonomic profile.
- | Briviact (brivaracetam) / UCB
Journal: Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein. (Pubmed Central) - Jul 24, 2021
Subchronic brivaracetam administration suppressed TNFα-induced activation of AMPA/glutamate receptor and hemichannel via inhibition of ectopic SV2A. These findings suggest that combined inhibition of vesicular and ectopic SV2A functions contribute to the antiepileptic/anticonvulsive mechanism of brivaracetam action.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Safety and Efficacy of Brivaracetam in Pediatric Refractory Epilepsy: A Single-Center Clinical Experience. (Pubmed Central) - Jul 22, 2021
One experienced tingling and dizziness. Our retrospective review suggests that brivaracetam is an effective therapy for refractory focal epilepsy in children older than 4 years of age.
- | Briviact (brivaracetam) / UCB
Journal: Seizures in palliative medicine: brivaracetam. (Pubmed Central) - Jul 15, 2021
We present three cases from 2019 to 2020 where subcutaneous brivaracetam has been successfully used in a Specialist Inpatient Palliative Care setting to manage seizures. Brivaracetam dosing is 1:1 conversion from oral:subcutaneous, with syringe driver doses ranging from 150 mg to 300 mg/24 hours being successfully used, with no adverse effects observed.
- || pregabalin / Generic mfg., sirolimus / Generic mfg., gabapentin / Generic mfg.
Review, Journal: Interaction of cannabidiol with other antiseizure medications: A narrative review. (Pubmed Central) - Jul 14, 2021
The existing literature is limited for some ASMs by studies having relatively small cohorts. As increasing numbers of patients use cannabidiol, specialists need to monitor closely for interactions clinically and with blood levels when required.
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Intravenous brivaracetam in status epilepticus: A multicentric retrospective study in Italy. (Pubmed Central) - Jul 14, 2021
BRV proved to be useful and safe for the treatment of SE. Time to seizures resolution appears shorter when it is administered in the early phases of SE.
- |||| brivaracetam / Generic mfg.
Enrollment open, Monotherapy: EXPAND: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - Jul 12, 2021
P2/3, N=160, Recruiting, Sponsor: UCB Biopharma SRL
Time to seizures resolution appears shorter when it is administered in the early phases of SE. Not yet recruiting --> Recruiting
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? - A case series. (Pubmed Central) - Jul 2, 2021
In the remaining case, oxcarbazepine was replaced by CBZ and added to a stable BRV dose...However, in the remaining six, the elevated CBZ-E levels were not associated with any tolerability problems. The importance of CBZ-E for adverse events under CBZ may have been overemphasized in the past and is not clinically impairing in most cases treated with the combination of BRV and CBZ.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: An uncommon case of nonconvulsive status epilepticus successfully treated with enteral Brivaracetam. (Pubmed Central) - Jun 30, 2021
The administration of new antiepileptic drugs (AEDs) such as BRV may result in significant clinical improvement in refractory cases of status epilepticus. The enteral administration of AEDs via NGT should always be considered for refractory cases of status epilepticus when standard iv treatment has failed or is not possible.
- || brivaracetam / Generic mfg.
Trial completion: A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects (clinicaltrials.gov) - Jun 28, 2021
P1, N=12, Completed, Sponsor: UCB Biopharma SRL
The enteral administration of AEDs via NGT should always be considered for refractory cases of status epilepticus when standard iv treatment has failed or is not possible. Active, not recruiting --> Completed
- | Briviact (brivaracetam) / UCB
Journal: Brivaracetam in absence status epilepticus. (Pubmed Central) - Jun 24, 2021
Active, not recruiting --> Completed No abstract available
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Adjunctive Brivaracetam in Indian Patients with Uncontrolled Focal Epilepsy: Results from a Pooled Analysis of Two Double-Blind, Randomized, Placebo-Controlled Trials. (Pubmed Central) - Jun 22, 2021
In the safety population (n = 104), most commonly reported TEAEs (reported by ≥5% of patients taking brivaracetam) were headache and cough; most TEAEs were mild or moderate in intensity. This pooled analysis has provided evidence that adjunct brivaracetam, was effective and well-tolerated in Indian patients with uncontrolled focal epilepsy.
- || Briviact (brivaracetam) / UCB
Review, Journal: Brivaracetam: How Well Does It Fare as an Anti-Epileptic? A Review. (Pubmed Central) - Jun 22, 2021
Our analysis provides moderate evidence for Brivaracetam as an effective agent as an early adjuvant in FOS. Its efficacy for several other indications needs further clinical trials and evaluation.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy. (Pubmed Central) - Jun 22, 2021
BRV reduces the power of the alpha band, in correlation with its sedative effects but not with its minor efficacy. Furthermore, the increase in theta band power can be considered as a predictor of scarce response to treatment, while an increase in the δ+θ/α+β index could be a possible predictor of AEs occurrence.
- || Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB, lamotrigine liquid oral suspension / OWP Pharma
Clinical, Review, Journal: Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults. (Pubmed Central) - Jun 10, 2021
The mechanisms underlying genetic generalised epilepsies, including genetic abnormalities, are unclear at present. As the pathophysiology is unravelled, this may lead to the development of novel therapies and improved outcomes for patients with these syndromes.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Brivaracetam: first Canadian experience in an intractable epilepsy population. (Pubmed Central) - Jun 8, 2021
As the pathophysiology is unravelled, this may lead to the development of novel therapies and improved outcomes for patients with these syndromes. No abstract available
- || brivaracetam / Generic mfg.
Enrollment closed: A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects (clinicaltrials.gov) - Jun 2, 2021
P1, N=12, Active, not recruiting, Sponsor: UCB Biopharma SRL
No abstract available Recruiting --> Active, not recruiting
- || Briviact (brivaracetam) / UCB
Clinical, Review, Journal, Real-world evidence: Brivaracetam Retention Rate and Seizure Outcomes in Patients with Drug-Resistant Focal Epilepsy Included in the Medical Need Program in Belgium: A Real-World, Multicenter, Chart Review. (Pubmed Central) - Jun 2, 2021
Recruiting --> Active, not recruiting Retention was high during 9 months of brivaracetam treatment in drug-resistant patients, including those previously/concomitantly treated with levetiracetam; 3-month seizure freedom increased from 3.2% after 3 months to 10.7% after 9 months of treatment.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
[VIRTUAL] Anakinra in the treatment of New-Onset Refractory Status Epilepticus: Our experience from a clinical case (Room Seville) - May 30, 2021 - Abstract #EAN2021EAN_1557;
We report a positive, although incomplete, response to anakinra. More evidence is required to support this indication.
- Fycompa (perampanel) / Eisai
[VIRTUAL] Third generation aeds in the elderly: use of perampanel in pharmacorresistant epilepsy (Room Seville) - May 30, 2021 - Abstract #EAN2021EAN_1539;
In our series, PER was well-tolerated even in polytherapy with 72% of patients improving seizures frequency, without cognitive or behavioral decline associated. Although further studies are necessary, PER could be a safe and effective option in these patients.
- pregabalin / Generic mfg.
[VIRTUAL] Comparative efficacy and safety of anti- epileptic drugs in paediatric populations: A network meta-analysis (CBW Room) - May 30, 2021 - Abstract #EAN2021EAN_1484;
In DSA, perampanel 8mg/d was as effective as brivaracetam 100mg/d (relative risk [RR]: 0.97; 95% credible interval [CrI]: 0.75–1.28), lacosamide 300mg/d (RR: 1.11; CrI: 0.78–1.66) and pregabalin 300mg/d (RR: 0.78; CrI: 0.58– 1.14) and more effective than eslicarbazepine 200mg/d (RR: 1.66; CrI: 1.06, 2.85) in achieving 50% seizure reduction. Perampanel has similar efficacy and safety as other third-generation AEDs and greater 50% and 75% seizure reduction rates than eslicarbazepine, at medium doses.
- || pregabalin / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
Clinical, Review, Journal: Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy. (Pubmed Central) - May 29, 2021
There is limited data for cannabidiol, clobazam, eslicarbazepine acetate, ethosuximide, rufinamide, vigabatrin and zonisamide, although the available evidence suggests these drugs are not associated with severe cognitive impairment. There was too little information to reach conclusions about the effects of brivaracetam, felbamate, gabapentin, pregabalin, retigabine, stiripentol or tiagabine.
- || pregabalin / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
Review, Journal: Mechanisms of action of currently used antiseizure drugs. (Pubmed Central) - May 28, 2021
Given this new understanding, attempts are being made to engineer specific small molecule, antisense and gene therapies that functionally reverse or structurally correct pathogenic defects in epilepsy syndromes. In the near future, these new therapies will begin a paradigm shift in the treatment of some rare genetic epilepsy syndromes, but targeted therapies will remain elusive for the vast majority of epilepsies until their causes are identified.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Effectiveness and Safety of Brivaracetam in Children. (Pubmed Central) - May 28, 2021
In the near future, these new therapies will begin a paradigm shift in the treatment of some rare genetic epilepsy syndromes, but targeted therapies will remain elusive for the vast majority of epilepsies until their causes are identified. No abstract available
- || brivaracetam / Generic mfg.
Enrollment open: A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects (clinicaltrials.gov) - May 27, 2021
P1, N=12, Recruiting, Sponsor: UCB Biopharma SRL
No abstract available Not yet recruiting --> Recruiting
- ||| Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
Retrospective data, Review, Journal, Adverse events: Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. (Pubmed Central) - May 20, 2021
This systematic review characterizes the incidences of irritability, anger, and aggression with BRV, LEV, PER, and TPM, and it provides robust real-world evidence demonstrating that switching from LEV to BRV may improve BAEs. While additional data remain valuable due to differences in methodology (which make comparisons difficult), these results improve understanding of the real-world incidences of discontinuations due to these BAEs in clinical practice and can aid in discussions and treatment decision-making with PWE.
- || Briviact (brivaracetam) / UCB
Clinical, Review, Journal: Efficacy and tolerability of intravenous brivaracetam for status epilepticus: A systematic review. (Pubmed Central) - May 15, 2021
Limited evidence from 5 uncontrolled studies involving a limited number of patients suggests that IV BRV may be efficacious and safe in terminating seizures among patients with SE or refractory SE. Further studies employing either prospective, controlled trials or registry-based study designs are essential to determine the definitive role of IV BRV in patients with SE.
- || brivaracetam / Generic mfg.
New P1 trial: A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects (clinicaltrials.gov) - May 11, 2021
P1, N=12, Not yet recruiting, Sponsor: UCB Biopharma SRL
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Development and Validation of an UHPLC-MS/MS Assay for the Therapeutic Monitoring of Brivaracetam Plasma Concentrations in Patients with Epilepsy. (Pubmed Central) - May 6, 2021
Further studies employing either prospective, controlled trials or registry-based study designs are essential to determine the definitive role of IV BRV in patients with SE. The present assay is faster and simpler than previously published analytical reports for brivaracetam in human plasma and is suitable for therapeutic drug monitoring.
- ||| ADX71149 / Addex
Enrollment open, Combination therapy: A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy (clinicaltrials.gov) - May 4, 2021
P2, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
The present assay is faster and simpler than previously published analytical reports for brivaracetam in human plasma and is suitable for therapeutic drug monitoring. Not yet recruiting --> Recruiting
- | Briviact (brivaracetam) / UCB
Journal: The Integrated Effects of Brivaracetam, a Selective Analog of Levetiracetam, on Ionic Currents and Neuronal Excitability. (Pubmed Central) - May 1, 2021
However, LEV had effects in the latter only. Collectively, our study demonstrated BRV's multiple ionic mechanism in electrically excitable cells and a potential concerted effect on neuronal excitability and hyperexcitability disorders.
- || Clinical, Review, Journal: New anti-seizure medication for elderly epilepsy patients - a critical narrative review. (Pubmed Central) - Apr 28, 2021
Dose adjustments are necessary for all ASMs used in the elderly with slow titration and lower target doses than in the regulatory trials. The adverse event profile does not significantly differ from that found in the general adult population.
- | brivaracetam / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) - Apr 28, 2021
P1/2, N=20, Recruiting, Sponsor: University of Minnesota
The adverse event profile does not significantly differ from that found in the general adult population. Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
- ||| oxcarbazepine / Generic mfg.
Journal, Adverse events: Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS). (Pubmed Central) - Apr 21, 2021
The majority of newer generation ASMs were not significantly associated with DILI. Future studies utilizing FAERS in conjunction with other data sources will be critical for the ongoing surveillance of DILI, particularly as newly marketed ASMs continue to enter into widespread clinical use.
- || Briviact (brivaracetam) / UCB
Clinical, Review, Journal: Potential role of brivaracetam in paediatric epilepsy. (Pubmed Central) - Apr 20, 2021
However, a positive response was also achieved in patients affected by encephalopathic epilepsies (e.g Jeavons' epilepsy, Dravet syndrome, Lennox Gastaut syndrome and juvenile myoclonic epilepsy), and ongoing studies are now testing BRV in order to widen its application to other forms of epilepsy and to test its effectivness when used in monotherapy. This review aims to provide a comprehensive analysis of the literature surrounding the efficacy and tolerability of BRV for paediatric patients.
- || Trileptal (oxcarbazepine) / Novartis
Clinical, Retrospective data, Journal, Monotherapy: A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy. (Pubmed Central) - Apr 17, 2021
In general, the 50% responder rate and treatment withdrawal rate tended to increase as the dose of the AEDs increased. The results from the current meta-analysis of the efficacy and safety data of various AEDs may provide insight into optimal pharmacotherapy for the treatment of focal epilepsy.
- brivaracetam / Generic mfg.
Trial completion: A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) - Apr 13, 2021
P3, N=10, Completed, Sponsor: UCB Biopharma S.P.R.L.
The results from the current meta-analysis of the efficacy and safety data of various AEDs may provide insight into optimal pharmacotherapy for the treatment of focal epilepsy. Recruiting --> Completed
- Xcopri (cenobamate) / SK Bio, Arvelle Therap
[VIRTUAL] The Budget Impact of Cenobamate for the Treatment of Uncontrolled Focal Epilepsy () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1076;
The nominal increase in pharmacy spend was balanced by a reduction in healthcare utilization costs, mostly due to fewer inpatient hospitalizations. Supported by SK Life Science, Inc.
- Briviact (brivaracetam) / UCB, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
[VIRTUAL] Comparative Economic Outcomes in Patients with Focal Seizures Initiating Adjunctive Eslicarbazepine Acetate Versus Brivaracetam As Their First Adjunctive Branded ASD () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1071;
Supported by SK Life Science, Inc. Among patients with FS, initiation of first branded adjunctive therapy with ESL was associated with significantly larger reductions in medical and non-ASD-related prescriptions charges compared to BRV.
- |||| ADX71149 / Addex
New P2 trial, Combination therapy: A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy (clinicaltrials.gov) - Apr 7, 2021
P2, N=160, Not yet recruiting, Sponsor: Janssen Research & Development, LLC